These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 17968710

  • 1. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
    Wang Y, Zhao Q, Ma S, Yang F, Gong Y, Ke C.
    IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of PKHD1 may cause S-phase entry via mTOR signaling pathway.
    Zheng R, Wang L, Fan J, Zhou Q.
    Cell Biol Int; 2009 Sep; 33(9):926-33. PubMed ID: 19524688
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma.
    Miyazawa M, Yasuda M, Fujita M, Kajiwara H, Hirabayashi K, Takekoshi S, Hirasawa T, Murakami M, Ogane N, Kiguchi K, Ishiwata I, Mikami M, Osamura RY.
    Pathol Int; 2009 Jan; 59(1):19-27. PubMed ID: 19121088
    [Abstract] [Full Text] [Related]

  • 4. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy.
    García-Maceira P, Mateo J.
    Oncogene; 2009 Jan 22; 28(3):313-24. PubMed ID: 18978810
    [Abstract] [Full Text] [Related]

  • 5. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
    Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, Atadja P, Pili R.
    Clin Cancer Res; 2008 Jun 01; 14(11):3589-97. PubMed ID: 18519793
    [Abstract] [Full Text] [Related]

  • 6. A quassinoid 6alpha-tigloyloxychaparrinone inhibits hypoxia-inducible factor-1 pathway by inhibition of eukaryotic translation initiation factor 4E phosphorylation.
    Jin X, Jin HR, Lee D, Lee JH, Kim SK, Lee JJ.
    Eur J Pharmacol; 2008 Sep 11; 592(1-3):41-7. PubMed ID: 18639543
    [Abstract] [Full Text] [Related]

  • 7. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
    Gibbons JJ, Abraham RT, Yu K.
    Semin Oncol; 2009 Dec 11; 36 Suppl 3():S3-S17. PubMed ID: 19963098
    [Abstract] [Full Text] [Related]

  • 8. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.
    Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, Milella M.
    Cancer Res; 2006 Jun 01; 66(11):5549-54. PubMed ID: 16740688
    [Abstract] [Full Text] [Related]

  • 9. Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells.
    Böhm A, Aichberger KJ, Mayerhofer M, Herrmann H, Florian S, Krauth MT, Derdak S, Samorapoompichit P, Sonneck K, Vales A, Gleixner KV, Pickl WF, Sperr WR, Valent P.
    Eur J Clin Invest; 2009 May 01; 39(5):395-405. PubMed ID: 19320940
    [Abstract] [Full Text] [Related]

  • 10. Suppression of the proliferation of hypoxia-Induced retinal pigment epithelial cell by rapamycin through the /mTOR/HIF-1α/VEGF/ signaling.
    Liu NN, Zhao N, Cai N.
    IUBMB Life; 2015 Jun 01; 67(6):446-52. PubMed ID: 25988388
    [Abstract] [Full Text] [Related]

  • 11. Effect of endothelial PAS domain protein 1 and hypoxia inducible factor 1alpha on vascular endothelial growth factor expression in human pancreatic carcinoma.
    Zhu DM, Li DC, Zhang ZX, Zhang XY.
    Chin Med J (Engl); 2008 Nov 20; 121(22):2258-64. PubMed ID: 19080330
    [Abstract] [Full Text] [Related]

  • 12. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells.
    Edinger AL, Linardic CM, Chiang GG, Thompson CB, Abraham RT.
    Cancer Res; 2003 Dec 01; 63(23):8451-60. PubMed ID: 14679009
    [Abstract] [Full Text] [Related]

  • 13. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells.
    Frost P, Shi Y, Hoang B, Lichtenstein A.
    Oncogene; 2007 Apr 05; 26(16):2255-62. PubMed ID: 17016437
    [Abstract] [Full Text] [Related]

  • 14. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR.
    Hou G, Xue L, Lu Z, Fan T, Tian F, Xue Y.
    Cancer Lett; 2007 Aug 18; 253(2):236-48. PubMed ID: 17360108
    [Abstract] [Full Text] [Related]

  • 15. Granulosa cell tumor with activated mTOR-HIF-1alpha-VEGF pathway.
    Miyazawa M, Yasuda M, Fujita M, Hirabayashi K, Hirasawa T, Kajiwara H, Muramatsu T, Miyazaki S, Harasawa M, Matsui N, Ogane N, Murakami M, Mikami M, Yanase T, Osamura RY.
    J Obstet Gynaecol Res; 2010 Apr 18; 36(2):448-53. PubMed ID: 20492406
    [Abstract] [Full Text] [Related]

  • 16. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.
    Clin Cancer Res; 2009 Mar 01; 15(5):1612-22. PubMed ID: 19223496
    [Abstract] [Full Text] [Related]

  • 17. [Inhibition of hypoxia-inducible factor 1alpha expression and tumor growth in SKOV3 ovarian cancer model by sirolimus].
    Jiang HY, Feng YJ.
    Zhonghua Fu Chan Ke Za Zhi; 2004 Jul 01; 39(7):474-7. PubMed ID: 15347472
    [Abstract] [Full Text] [Related]

  • 18. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ.
    Namba R, Young LJ, Abbey CK, Kim L, Damonte P, Borowsky AD, Qi J, Tepper CG, MacLeod CL, Cardiff RD, Gregg JP.
    Clin Cancer Res; 2006 Apr 15; 12(8):2613-21. PubMed ID: 16638874
    [Abstract] [Full Text] [Related]

  • 19. [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma].
    Shuuin T, Karashima H.
    Gan To Kagaku Ryoho; 2009 Jul 15; 36(7):1076-9. PubMed ID: 19620795
    [Abstract] [Full Text] [Related]

  • 20. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation.
    Mateo-Lozano S, Tirado OM, Notario V.
    Oncogene; 2003 Dec 18; 22(58):9282-7. PubMed ID: 14681687
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.